Principia Biopharma Inc.
Principia Biopharma Inc. (PRNB): 5 pipeline candidates · ~36 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
36.2 months
6% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for Principia Biopharma Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$171.1M
Quarterly Burn
$27.0M
Runway
36.2 mo
Revenue
$50.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| prn1008 | Phase 3 |
| prn1371 | Phase 1 |
| prn2246/sar442168 | Phase 1 |
| prn473 | Phase 2 |
| rilzabrutinib sar444671 | Phase 1 |
Frequently asked questions
How many drug candidates are in Principia Biopharma Inc.'s pipeline?
Principia Biopharma Inc. (PRNB) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Principia Biopharma Inc.'s lead drug candidate?
Principia Biopharma Inc.'s most advanced tracked candidate is prn1008 (Phase 3) for Immune thrombocytopenic purpura (ITP).
What is Principia Biopharma Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Principia Biopharma Inc. has approximately 36.2 months of cash runway.
Who is the CEO of Principia Biopharma Inc.?
Martin Babler is the chief executive officer of Principia Biopharma Inc. (PRNB).
Get the full picture on Principia Biopharma Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.